Novel strategies for
pharmacotherapy of depression
by
Maubach KA, Rupniak NM, Kramer MS,
Hill RG Merck Sharp & Dohme
Neuroscience Research Centre Terlings Park,
Eastwick Road, Harlow, Essex, CM20 2QR, UK.
karen_maubach@merck.com
Curr Opin Chem Biol 1999 Aug; 3(4): 481-8

ABSTRACT

Modulating monoamine activity as a therapeutic strategy continues to dominate antidepressant research, with a recent emphasis on agents with multiple targets, including combined serotonin/noradrenaline re-uptake inhibitors and numerous serotonin receptor ligands. An important new development has been the emergence of potential novel mechanisms of action, notably modulation of the activity of neuropeptides substance P and corticotrophin-releasing factor, and the intracellular messenger cyclic adenosine monophosphate. Efforts in this area have recently been rewarded by the demonstration of antidepressant efficacy of the substance P receptor antagonist MK-0869.

cAMP
SAMe
DHEA
Inositol
YKP10A
Antisense
Hypericum
21st Century
Pregnenolone
Buprenorphine
Neuropeptide-Y
NMDA antagonists
New antidepressants
Enkephalinase inhibitors
Substance P antagonists
Neurokinins/substance P
Old and new antidepressants
New substance P antagonists
Nitric oxide synthase inhibitors
Antidepressants and new brain cells
Mood enhancement via stem cell therapy

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family